Kalaris Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate
Benzinga Newsdesk 5 hours ago
NewsEarningsEarnings Beats
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 28.13 percent increase over losses of $(0.64) per share
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 28.13 percent increase over losses of $(0.64) per share from the same period last year.